Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Managing Editor, US Commercial News
California, USA
23+ years of experience
Scrip
By Mandy Jackson 14 Nov 2022
Drug developers and payers are coming together long before product approvals to work out payment options for high-cost, high-impact cell and gene therapies, but challenges like portability of commercially insured patients and Medicaid best price requirements remain.
Scrip
By Mandy Jackson 25 Nov 2021
Private Company Edition: Recent VC financings across biopharma sectors include three major mega-rounds as Generate Biomedicines bringing in $370m, followed by $250m for Acelyrin and $125m for Chroma Medicine. Also, Treadwell raised a $91m series B and Ncardia brought in $60m-plus.
Scrip
By Mandy Jackson 02 Nov 2021
The US FDA has extended the user fee date by three months for the partners’ BCMA-targeting CAR-T therapy but its first-to-market rival is facing manufacturing challenges that limit access to treatment.
Scrip
By Mandy Jackson 05 Oct 2021
With 88 initial public offerings in the US through the end of the third quarter of 2021, the biopharma industry is two IPOs ahead of the full-year 2020 total, but with an average return of -4% momentum may slow.
Scrip
By Mandy Jackson 10 Aug 2021
For Biogen/Eisai’s success with Aduhelm, there were 93 failures in the anti-amyloid field. Scrip took a look back at how the pipeline for amyloid-targeting Alzheimer’s drugs progressed over roughly the past decade to showcase exactly how difficult the Alzheimer’s space has been.
Pink Sheet
By Mandy Jackson 27 Nov 2020
Trump administration wants the HIV drug maker to license HHS patents related to pre-exposure prophylaxis. Lawsuit follows Gilead’s request in August for the USPTO’s PTAB to conduct an inter partes review of the four-year-old patents.
Topic Infectious Diseases
Scrip
By Mandy Jackson 27 Nov 2020
Private Company Edition: Atea and Phlow receive big money for big COVID-19 problems – treatments and manufacturing capacity. Also, Cowen raises a $493m fund and antifungal developer Amplyx increases series C round to $90m, among other recent VC deals.
Topic Coronavirus Financing Innovation
Scrip
By Mandy Jackson 27 Nov 2020
Phase III results support early 2020 filings for what could be the RNAi specialist’s third commercial product, but two competing drugs for primary hyperoxaluria from Dicerna and OxThera aren’t far behind.
Scrip
By Mandy Jackson 17 Nov 2020
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Scrip
By Mandy Jackson 09 Oct 2020
Results from a Phase II/III study for VIR-7831 in the prevention of hospitalization due to COVID-19 are expected in late 2020 and early 2021.
Scrip
By Mandy Jackson 21 Sep 2020
Olumiant (baricitinib) plus Gilead’s Veklury (remdesivir) provided a statistically significant reduction in time to recovery versus remdesivir alone for hospitalized patients in US NIAID’s ACTT-2 clinical trial.
Scrip
By Mandy Jackson 01 Jul 2020
A five-day course will cost $2,340 for governments in developed countries and $3,120 for commercial payers. The US will get 100% of remdesivir manufactured by Gilead in July.
Topic Coronavirus
Scrip
By Mandy Jackson 06 Mar 2020
ICER’s final report on new acute migraine treatments said the drugs are similarly beneficial when patients don’t respond to or can’t take triptans, but found Reyvow is not as cost effective as Ubrelvy and rimegepant.
Topic Coronavirus
Scrip
By Mandy Jackson 22 Jan 2020
Updates and coverage of the 2020 J.P. Morgan Healthcare Conference in San Francisco.
Scrip
By Mandy Jackson 18 Oct 2019
One regenerative medicine for an ultra-rare disease may have a small impact, but payers will be flooded with dozens of new cell and gene therapies over the next few years. Enzyvant, Novartis and Spark share how they are positioning their complex products.
Topic Cell & Gene Therapy
Scrip
25 Jul 2022
Scrip
22 Jul 2022
Scrip
21 Jul 2022
Scrip
20 Jul 2022
Scrip
15 Jul 2022
Scrip
14 Jul 2022
Scrip
13 Jul 2022
Scrip
12 Jul 2022
Scrip
11 Jul 2022
Scrip
08 Jul 2022
Scrip
06 Jul 2022
Scrip
05 Jul 2022
Scrip
04 Jul 2022
Scrip
01 Jul 2022
Scrip
29 Jun 2022
